DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Trelstar Depot (Triptorelin Pamoate) - Summary

 
 



TRELSTAR DEPOT SUMMARY

B1
Revised: September 2005
Watson Pharma, Inc.
TRELSTAR® DEPOT 3.75 mg
(triptorelin pamoate for injectable suspension)

TRELSTAR DEPOT contains a pamoate salt of triptorelin, and triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH or GnRH) with greater potency than the naturally occurring LHRH.

TRELSTAR DEPOT is indicated in the palliative treatment of advanced prostate cancer. It offers an alternative treatment for prostate cancer when orchiectomy or estrogen administration are either not indicated or unacceptable to the patient.


See all Trelstar Depot indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Trelstar Depot (Triptorelin)

OncoBriefs: PDE5 Use and Prostate Cancer, H&N, Cervical Ca (CME/CE)
Source: MedPageToday.com - medical news plus CME for physicians [2015.01.24]
(MedPage Today) -- Erectile dysfunction drugs linked to higher risk of biochemical recurrence after prostatectomy.

In women with Alzheimer's disease, prostate cancer drug slows memory loss
Source: Prostate / Prostate Cancer News From Medical News Today [2015.01.23]
Women with Alzheimer's disease showed stable cognition for a year when a drug that is more commonly used to treat advanced prostate cancer was added to their drug regimen, according to a new study...

Overcoming treatment resistance in prostate cancer: Roswell Park team proposes a new strategy
Source: Genetics News From Medical News Today [2015.01.20]
Researchers have discovered what may be a promising new approach for controlling aggressive, treatment-resistant forms of prostate cancer.

Some men with advanced prostate cancer benefit from high-dose testosterone therapy
Source: Endocrinology News From Medical News Today [2015.01.12]
In a surprising paradox, the male hormone testosterone, generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers and also may reverse resistance...

New study findings help physicians and patients determine prostate cancer risk
Source: Prostate / Prostate Cancer News From Medical News Today [2015.01.12]
A discovery by researchers at Huntsman Cancer Institute at the University of Utah shows that looking at whether a man's uncles and great-grandparents, among other second- and third-degree...

more news >>

Published Studies Related to Trelstar Depot (Triptorelin)

Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. [2011.07.20]
CONTEXT: Premenopausal patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect are yet available. OBJECTIVE: To determine the effect of the temporary ovarian suppression obtained by administering the gonadotropin-releasing hormone analogue triptorelin during chemotherapy on the incidence of early menopause in young patients with breast cancer undergoing adjuvant or neoadjuvant chemotherapy... CONCLUSION: The use of triptorelin-induced temporary ovarian suppression during chemotherapy in premenopausal patients with early-stage breast cancer reduced the occurrence of chemotherapy-induced early menopause. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00311636.

A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis. [2011.07]
PURPOSE: To compare the role of an aromatase inhibitor (letrozole) with a GnRH agonist (triptorelin) versus case control on the pregnancy rate and recurrence of symptoms and signs in patients with endometriosis... CONCLUSION: Pregnancy rate and endometriosis recurrence rate are comparable among the 3 groups.

Synchronization of ovulation and fertility in weaned sows treated with intravaginal triptorelin is influenced by timing of administration and follicle size. [2011.01.15]
A 100 mug dose of triptorelin was tested for synchronizing ovulation in sows. In Experiment 1, conducted in April through June, sows (n = 125) were assigned to Control (untreated), TG-96 (Triptorelin Gel (TG) given intravaginally at 96 h post-weaning), or TG-E (given intravaginally at estrus)... However, ovulation induction and timed AI success may benefit from an approach that ensures sows have adequate follicle development at time of treatment.

A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. [2010.01]
OBJECTIVE: To examine and compare the efficacy and safety of GnRH agonist (GnRHa) vs. aromatase inhibitor in premenopausal women with leiomyomas.

A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. [2009.01.08]
OBJECTIVE: To examine and compare the efficacy and safety of GnRH agonist (GnRHa) vs. aromatase inhibitor in premenopausal women with leiomyomas.Rapid onset of action and avoidance of initial gonadotropin flare with an aromatase inhibitor may be advantageous for short-term management of women with myomas of any size who are to be managed transiently and who wish to avoid surgical intervention, specifically women with unexplained infertility having uterine myoma.

more studies >>

Clinical Trials Related to Trelstar Depot (Triptorelin)

Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg [Recruiting]
The purpose of this study is to demonstrate the pharmacodynamic equivalence of triptorelin pamoate (Pamorelin® LA 11. 25 mg), applied either IM or SC, in terms of the area under the curve [AUC1-85day] for serum testosterone in patients with advanced prostate cancer.

Study to Assess the Non-Inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT) [Recruiting]
The active ingredient of Pamorelin® 11,25 mg is Triptorelin. Triptorelin is a substitute for a natural hormone produced in the body called Gonadotrophin-releasing hormone (GnRH). GnRH is a hormone secreted by hypothalamus (a gland located in brain) and controls the production of sex hormones (eg testosterone in men) in other organs in the body. The growth of prostate cancer cells, one of the most common cancers in men, is induced by the hormone testosterone. Hormono-therapy is one of treatments available to treat this type of disease by controlling the testosterone serum level. Pamorelin® 11,25 mg is normally injected in the muscle but this type of injection is not suitable for every patient. Therefore the primary purpose of this study is to assess the non-inferiority of the 12-week triptorelin formulation Pamorelin® 11,25 mg administered via subcutaneous (SC) injection as compared to Pamorelin® 11,25 mg administered via standard intramuscular (IM) injection based on the percentage of patients presenting a testosterone level ≤ 50 ng/dl at week 24.

Efficacy, Safety, and PK of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty [Recruiting]
The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22. 5 mg 6-month formulation in 44 patients suffering from central precocious puberty. The null hypothesis of the study is that the proportion of patients achieving LH suppression to prepubertal levels at Month 6 is 80%.

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer [Recruiting]
The study will investigate the efficacy, pharmacokinetics and safety of triptorelin embonate 22. 5 mg 6-month formulation administered by subcutaneous injections in patients with prostate cancer

Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty [Recruiting]
The purpose of the study is to assess the efficacy of triptorelin 11. 25 mg pamoate in the delay of premature onset of puberty in girls less than 9 years and boys less than 10 years. This is measured by assessing the proportion of children who have a suppressed Luteinizing Hormone (LH) response to Gonadotropin Releasing Hormone (GnRH) test performed 3 months after injection with triptorelin 11. 25 mg.

more trials >>


Page last updated: 2015-01-24

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014